LRMR Larimar Therapeutics Inc

$LRMR I expect there will be a lot of newsflow beyond the known catalysts with the FDA a few months from now given that the company will be working on getting approvals in several regions (UK/EU/CDA/OZ) once the BLA package is fully submitted.

$LRMR 3 Catalysts within about 2 months time now. 3 catalysts that we know about. Unless management does a deal for the EU market... they could even do a deal like $TGTX did where you retain the right to call back the EU rights in the event of a buyout within a year, that would keep Deerfield happy, who's exit strategy is to put us up for auction once approval is secured...

$LRMR hard to believe this we keep going down after the person they just hired it couldn’t be any more obvious that they believe they are going to get approval and go to market

$LRMR Rare Disease companies get bought out more frequently and for higher premiums than any other biotech niche. Paytience will be rewarded.

$LRMR did Deerfield regret and cut their losses for year end tax harvest or what? Price has large dump in volume this week. We all know the clinical trial results is fragile at this moment with fda. Until then, nobody knows how the clinical data mature, except probably Deerfield and insiders? And, why didn't they load the boat at this dirt cheap price. Or, is it really dirt? No position. Watching on the sidelines. Good luck!

$LRMR 3,278,000 shares went through in 4 trades AH. I wonder if Blue Owl caused this. We will find out tomorrow if they are done.

$LRMR Just can't figure this out and I got stop lossed out of positions! Now have to reassess to reenter or wait for reversal trend or clarification on this drastic pull back.

$LRMR Would FDA approve a drug with this safety profile ? "...Anaphylaxis occurred in 10 of 41 participants in an open-label study, and 21 participants discontinued, the company said.."

$LRMR It seems likely that it will go to test the 1.6 to 1.8 support range by the end of October. Information void Unfulfilled promises Tax-Loss Harvesting Lack of momentum Small-cap biotech weakness since mid-August It’s a great stock, but the lack of buying at key support shows the market finds it unappealing. Based on the Investor Event, the BLA will likely be submitted between late November and early December... Still, management's recent response is deeply disappointing.

$LRMR BLA announcement and 1 patient dosed is imminent. Question is, how low do we go before that?

$LRMR Re-entering the position 🔄 It’s sad that management broke their promises 😢, but I feel like the risk-reward profile is just too good at this price point. Looking at management's past behavior and the competitive landscape, I honestly expected them to break their word. For now, the most important thing for this company is 'accelerated approval.' (Collecting data on naive patients is far more critical than starting Phase 3.) If they don't update us with any new info along with the first patient dosing news, I think that will be the time to start reducing position sizes or rebalancing. That would be the moment to seriously question a company that's just mindlessly burning through all that cash before achieving 'accelerated approval.' Oh, one last thing—I occasionally see Lexeo being mentioned, and while it's a great company, if you want to make a comparison, matching it against Solid Biosciences will give you a much better understanding of the FA indication and LRMR.

$LRMR This one is really befuddling to me. I don't see the reason for getting slammed, what am I missing? They fall behind schedule? Adverse event? Dumped more shares on the market?

$LRMR I agree this is good news. I think it would be down more without this new hire. All my Bio's are down a LOT. This could have done better if they did what they said they would and dosed the first patient in Q3. It's either an execution problem or patients aren't that interested in the drug. I'm a member of Bio5C. Over the years, everyone there has noticed that, across hundreds of tickers, being slow to dose and slow to populate a trial directly correlates with overall success. The faster a Bio populates a trial, the more directly it correlates with drug approval.

$LRMR $LRMR keep delaying and cash burn. Probably delay submission to year 2027 too! With her lips service and track record. Just saying

$LRMR The first patient in the Phase 3 clinical trial was initially expected to be treated during the third quarter of 2026. The September 30 deadline has now passed. Why has there still been no update or official communication regarding this milestone?

$LRMR biotech recovery, but this POS did not and did the opposite. Huge volume dump. 5x more volume. What am I missing here? Someone know something and that's not me. Am on the sidelines.

$LRMR problem is high cashburn. Cash into Q3 2027 means raise within 2-4 months. Big dilution coming in catalyst desert. Need to get those out of the way or drifting down further…..newbies getting schooled in microcap dynamics.

$LRMR Brief Summary The efficacy of SC administration of nomlabofusp compared to placebo at Week 72 on the Clinical Global Impression of Severity (CGI-S) score The safety and tolerability of SC administration of nomlabofusp Official Title A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia Conditions Friedreich Ataxia Friedreich's Ataxia Intervention/Treatment Drug: Nomlabofusp Drug: Placebo Other Study ID Numbers CLIN-1601-301 2025-521628-31-00 ( EU Trial (CTIS) Number ) 2025 ( U.S. NIH Grant/Contract ) Study Start (Estimated) 2026-10-26 Primary Completion (Estimated) 2029-07 Study Completion (Estimated) 2029-12 En